keyword
MENU ▼
Read by QxMD icon Read
search

asacol

keyword
https://www.readbyqxmd.com/read/27158764/oral-5-aminosalicylic-acid-for-maintenance-of-remission-in-ulcerative-colitis
#1
REVIEW
Yongjun Wang, Claire E Parker, Brian G Feagan, John K MacDonald
BACKGROUND: Oral 5-aminosalicylic (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs were more effective than placebo but had a statistically significant therapeutic inferiority relative to SASP. This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations used for maintenance of remission in quiescent ulcerative colitis...
2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27101467/oral-5-aminosalicylic-acid-for-induction-of-remission-in-ulcerative-colitis
#2
REVIEW
Yongjun Wang, Claire E Parker, Tania Bhanji, Brian G Feagan, John K MacDonald
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs in doses of at least 2 g/day, were more effective than placebo but no more effective than SASP for inducing remission in ulcerative colitis. This updated review includes more recent studies and evaluates the efficacy and safety of 5-ASA preparations used for the treatment of mild to moderately active ulcerative colitis...
April 21, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26831607/healing-acceleration-of-acetic-acid-induced-colitis-by-marigold-calendula-officinalis-in-male-rats
#3
Nader Tanideh, Akram Jamshidzadeh, Masood Sepehrimanesh, Masood Hosseinzadeh, Omid Koohi-Hosseinabadi, Asma Najibi, Mozhdeh Raam, Sajad Daneshi, Seyedeh-Leili Asadi-Yousefabad
BACKGROUND/AIM: Ulcerative colitis (UC) is a type of chronic inflammatory bowel disease with unknown etiology. Several therapeutic strategies such as consumption of medicinal plants have been used for its treatment. The aim of this study was to evaluate healing effects of Calendula officinalis hydroalcoholic extract in experimentally induced UC in rat. MATERIALS AND METHODS: Ninety-six rats, weighing 200 ± 20 g, were randomly divided into eight equal groups. UC induced by 3% acetic acid and oral doses of C...
January 2016: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/26106471/report-of-a-rare-case-of-nasal-mucosa-pyoderma-vegetans-in-a-patient-with-ulcerative-colitis
#4
Homayoon Vahedi, Neda Nozari, Masoud Sotoudeh
Some dermatologic manifestations are common in ulcerative colitis (UC). Herein, we present a 36-year-old woman with ulcerative colitis and uncommon nasal mucosa pyoderma vegetans. The patient presented to our hospital with symptoms of active colitis and a concomitant 3×4×5 cm dermato-mucosal lesion in her left nasal lumen. After surgery of the mucosal lesion, the treatment for her active colitis was initiated with intravenous infliximab and oral asacol. After a 1-year follow-up, no sign of recurrence favoring mucosal lesion was noted and symptoms of ulcerative colitis were managed properly...
April 2015: Middle East Journal of Digestive Diseases
https://www.readbyqxmd.com/read/26070463/review-uk-medicines-likely-to-be-affected-by-the-proposed-european-medicines-agency-s-guidelines-on-phthalates
#5
REVIEW
Lisa Jamieson, William McCully
BACKGROUND: Phthalates are excipients in drug formulations. However, concerns have been raised about the effects of particular phthalates on reproduction and development. As a result the EMA has introduced guidelines for permitted daily exposure (PDE) limits for certain phthalates. Therefore, the objective of this study was to identify UK licensed medicines that contain the relevant phthalates and determine if they fall within the recommended PDE. METHODS: The eMC was used to identify which UK licensed medicines contain the phthalates in question...
June 13, 2015: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/25989323/two-stage-single-compartment-models-to-evaluate-dissolution-in-the-lower-intestine
#6
Constantinos Markopoulos, Maria Vertzoni, Mira Symillides, Filippos Kesisoglou, Christos Reppas
The purpose was to propose two-stage single-compartment models for evaluating dissolution characteristics in distal ileum and ascending colon, under conditions simulating the bioavailability and bioequivalence studies in fasted and fed state by using the mini-paddle and the compendial flow-through apparatus (closed-loop mode). Immediate release products of two highly dosed active pharmaceutical ingredients (APIs), sulfasalazine and L-870,810, and one mesalamine colon targeting product were used for evaluating their usefulness...
September 2015: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/25951927/release-of-5-aminosalicylic-acid-5-asa-from-mesalamine-formulations-at-various-ph-levels
#7
Adeyinka Abinusawa, Srini Tenjarla
INTRODUCTION: Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate the release of 5-ASA from available oral mesalamine formulations in physiologically relevant pH conditions. METHODS: Release of 5-ASA from 6 mesalamine formulations (APRISO®, Salix Pharmaceuticals, Inc., USA; ASACOL® MR, Procter & Gamble Pharmaceuticals UK Ltd...
May 2015: Advances in Therapy
https://www.readbyqxmd.com/read/25721685/gastrointestinal-release-behaviour-of-modified-release-drug-products-dynamic-dissolution-testing-of-mesalazine-formulations
#8
Alvaro Goyanes, Grace B Hatton, Hamid A Merchant, Abdul W Basit
The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dynamic conditions of the gastrointestinal tract. Monolithic and multi-particulate mesalazine formulations with pH-dependent and/or independent release mechanisms were evaluated (Asacol(®) 800, Octasa(®), Mezavant(®) XL, Salofalk(®), Pentasa(®)), and each of the products displayed a distinctive dissolution profile...
April 30, 2015: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/25429174/healing-effect-of-pistacia-atlantica-fruit-oil-extract-in-acetic-acid-induced-colitis-in-rats
#9
Nader Tanideh, Samira Masoumi, Massood Hosseinzadeh, Ali Reza Safarpour, Hoda Erjaee, Omid Koohi-Hosseinabadi, Salar Rahimikazerooni
BACKGROUND: Considering the anti-oxidant properties of Pistacia atlantica and lack of data regarding its efficacy in the treatment of ulcerative colitis, this study aims at investigating the effect of the Pistacia atlantica fruit extract in treating experimentally induced colitis in a rat model. METHODS: Seventy male Sprague-Dawley rats (weighing 220±20 g) were used. All rats fasted 24 hours before the experimental procedure. The rats were randomly divided into 7 groups, each containing 10 induced colitis with 2ml acetic acid (3%)...
November 2014: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/25392847/urinary-phthalate-metabolite-concentrations-among-men-with-inflammatory-bowel-disease-on-mesalamine-therapy
#10
Elizabeth J Hait, Antonia M Calafat, Russ Hauser
BACKGROUND: Phthalates, a family of compounds used in a variety of consumer products, are reproductive and developmental toxicants in experimental animals. One of these phthalates, dibutyl phthalate (DBP), is an inactive ingredient in the coating of Asacol. AIM: To determine if men with inflammatory bowel disease taking Asacol have higher urinary concentrations of monobutyl phthalate (MBP), a metabolite of DBP, compared to the general population in the United States...
October 20, 2014: Endocrine Disruptors
https://www.readbyqxmd.com/read/24459470/effects-of-carum-carvi-l-caraway-extract-and-essential-oil-on-tnbs-induced-colitis-in-rats
#11
A Keshavarz, M Minaiyan, A Ghannadi, P Mahzouni
Carum carvi L. (Apiaceae family) or caraway is a common household plant grown around the world including Iran. Caraway fruits are used as flavoring agent in foods and beverages, and have various traditional uses in ethnomedicine. Anti-inflammatory, spasmolytic, antimicrobial, antioxidant, carminative and immunomodulatory properties of caraway suggest that it might exert beneficial effects on inflammatory bowel disease (IBD). Therefore, this study was carried out to investigate the effects of caraway hydroalcoholic extract (CHE) and its essential oil (CEO) in an immunological model of colitis in rats induced by trinitrobenzene sulfonic acid (TNBS)...
January 2013: Research in Pharmaceutical Sciences
https://www.readbyqxmd.com/read/24111938/the-study-of-marketed-and-experimental-formulation-approaches-enabling-site-specific-delivery-of-mesalamine-in-patients-with-inflammatory-bowel-disease
#12
REVIEW
Irina Kadiyala, Dylan Jacobs
This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso(®), Asacol(®), Lialda(®) and Pentasa(®)) and non-marketed formulations are reviewed and explained by decoding formulation specifics that enable the site specific delivery for the treatment of inflammatory bowel disease.
April 2014: Recent Patents on Drug Delivery & Formulation
https://www.readbyqxmd.com/read/23528626/the-role-of-centralized-reading-of-endoscopy-in-a-randomized-controlled-trial-of-mesalamine-for-ulcerative-colitis
#13
RANDOMIZED CONTROLLED TRIAL
Brian G Feagan, William J Sandborn, Geert D'Haens, Suresh Pola, John W D McDonald, Paul Rutgeerts, Pia Munkholm, Ulrich Mittmann, Debra King, Cindy J Wong, Guangyong Zou, Allan Donner, Lisa M Shackelton, Denise Gilgen, Sigrid Nelson, Margaret K Vandervoort, Marianne Fahmy, Edward V Loftus, Remo Panaccione, Simon P Travis, Gert A Van Assche, Séverine Vermeire, Barrett G Levesque
BACKGROUND & AIMS: Interobserver differences in endoscopic assessments contribute to variations in rates of response to placebo in ulcerative colitis (UC) trials. We investigated whether centralized review of images could reduce these variations. METHODS: We performed a 10-week, randomized, double-blind, placebo-controlled study of 281 patients with mildly to moderately active UC, defined by an Ulcerative Colitis Disease Activity Index (UCDAI) sigmoidoscopy score ≥2, that evaluated the efficacy of delayed-release mesalamine (Asacol 800-mg tablet) 4...
July 2013: Gastroenterology
https://www.readbyqxmd.com/read/23426454/a-randomized-controlled-study-of-mesalamine-after-acute-diverticulitis-results-of-the-diva-trial
#14
RANDOMIZED CONTROLLED TRIAL
Neil Stollman, Simon Magowan, Fergus Shanahan, Eamonn M M Quigley
BACKGROUND/AIMS: We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis. METHODS: This was a 1-year double-blind, randomized, placebo-controlled study in which patients with computed tomography scan confirmed acute diverticulitis received placebo, mesalamine, or mesalamine+Bifidobacterium infantis 35624 (Align) for 12 weeks and followed for 9 additional months. Efficacy was assessed using a global symptom score (GSS) of 10 symptoms (abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus, urgency, painful straining, and dysuria)...
August 2013: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/23333816/medications-as-a-potential-source-of-exposure-to-phthalates-among-women-of-childbearing-age
#15
Sonia Hernández-Díaz, Yung-Cheng Su, Allen A Mitchell, Katherine E Kelley, Antonia M Calafat, Russ Hauser
OBJECTIVE: To evaluate the association between the use of medications potentially containing phthalates and urinary concentrations of specific phthalate metabolites around conception. METHODS: Women enrolled in the Environment and Reproductive Health project from 2006 to 2009 completed questionnaires about the use of medications and provided multiple urine samples before and after conception. We compared the mean urinary concentration of phthalate metabolites between users of phthalate containing medications and a matched unexposed control group...
June 2013: Reproductive Toxicology
https://www.readbyqxmd.com/read/23181094/validation-and-optimization-of-experimental-colitis-induction-in-rats-using-2-4-6-trinitrobenzene-sulfonic-acid
#16
A Motavallian-Naeini, S Andalib, M Rabbani, P Mahzouni, M Afsharipour, M Minaiyan
Trinitrobenzene sulfonic acid (TNBS)-induced colitis is one of the most common methods for studying inflammatory bowel disease in animal models. Several factors may, however, affect its reproducibility, rate of animal mortality, and macroscopic and histopathological outcomes. Our aim was to validate the main contributing factors to this method and compare the effects of different reference drugs upon remission of resultant colon injuries. TNBS was dissolved in 0.25 ml of ethanol (50% v/v) and instilled (25, 50, 100 and 150 mg/kg) intracolonically to the male Wistar rats...
July 2012: Research in Pharmaceutical Sciences
https://www.readbyqxmd.com/read/23076890/oral-5-aminosalicylic-acid-for-maintenance-of-remission-in-ulcerative-colitis
#17
REVIEW
Brian G Feagan, John K Macdonald
BACKGROUND: Oral 5-aminosalicylic (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs were more effective than placebo but had a statistically significant therapeutic inferiority relative to SASP. This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations used for maintenance of remission in quiescent ulcerative colitis...
2012: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/23076889/oral-5-aminosalicylic-acid-for-induction-of-remission-in-ulcerative-colitis
#18
REVIEW
Brian G Feagan, John K Macdonald
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs in doses of at least 2 g/day, were more effective than placebo but no more effective than SASP for inducing remission in ulcerative colitis. This updated review includes more recent studies and evaluates the efficacy and safety of 5-ASA preparations used for the treatment of mild to moderately active ulcerative colitis...
2012: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/22783919/double-blind-placebo-controlled-study-of-mesalamine-in-post-infective-irritable-bowel-syndrome-a-pilot-study
#19
RANDOMIZED CONTROLLED TRIAL
Ashok K Tuteja, John C Fang, Manal Al-Suqi, Gregory J Stoddard, Devon C Hale
OBJECTIVE: Post-infective irritable bowel syndrome (PI-IBS) is characterized by continuing symptoms of irritable bowel syndrome, typically diarrhea-predominant, following an episode of acute gastroenteritis. There is often an increase in sub-epithelial inflammatory and neuroendocrine cells on colonic mucosal biopsy. Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease. The goal of this study was to compare mesalamine to placebo on symptoms and quality-of-life (QOL) in PI-IBS...
October 2012: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/22644716/simulated-comparison-of-topical-and-oral-formulations-of-5-aminosalicylate-for-the-treatment-of-ulcerative-colitis
#20
COMPARATIVE STUDY
Derrick J Stobaugh, Parakkal Deepak, Matthew Thorpe, Bruce Hannon, Eli D Ehrenpreis
BACKGROUND: 5-Aminosalicylate (5-ASA) formulations are approved for the treatment of ulcerative colitis (UC). Determination of the colonic pharmacokinetics of 5-ASA is challenging. A dynamic model of 5-ASA colonic amounts after oral delayed-release 5-ASA (Asacol), oral extended delayed-release 5-ASA (Lialda), 5-ASA enema (Rowasa), foam and suppositories (Canasa) was developed to determine the colonic kinetics of these agents. METHODS: We created a model with Stella software...
February 2013: Inflammatory Bowel Diseases
keyword
keyword
40893
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"